Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Closes $400M DiaMed Acquisition

NEW YORK (GenomeWeb News) - Bio-Rad said today that it has closed its acquisition of DiaMed Holding, a developer of blood-typing reagents and screening tools, in a transaction worth approximately 477 million Swiss francs ($405.8 million).
 
Bio-Rad announced its plans to acquire DiaMed in May.
 
The company said it completed the purchase of around 77.7 percent of DiaMed’s outstanding shares today. DiaMed holds around 9.6 percent of its outstanding shares as treasury shares, and Bio-Rad said it plans to acquire the remaining outstanding shares within the next year.
 
DiaMed sells a line of reagents and instruments used in blood typing and screening. The Swiss firm has annual sales of around $200 million and around 800 employees worldwide.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.